Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2018-12-17 Report Publication Anno…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys AG: Corporate Calendar 2019 (news with additional features)
Report Publication Announcement Classification · 99% confidence The document is titled "MorphoSys AG: Corporate Calendar 2019" and explicitly lists future dates for key corporate events, including 'Publication of Interim Statement / Report', 'Conference Call', and 'Annual General Meeting'. This content is an announcement detailing the schedule of future corporate events and financial reporting dates, rather than the reports themselves (like 10-K or IR) or a transcript (CT). Since it is a general announcement disseminated via DGAP (a common regulatory news service), and it doesn't fit perfectly into specific categories like DIV, ER, or AGM-R (as it's the calendar, not the AGM material itself), the most appropriate classification is the general regulatory announcement fallback category, RNS, as it serves as a broad corporate news release detailing future scheduled events.
2018-12-17 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in voting rights percentages held by Invesco Ltd. in MorphoSys AG, referencing German Securities Trading Act (WpHG) articles. This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of 'Major Shareholding Notification' (MRQ). Although it is disseminated via DGAP (which often carries RNS filings), the specific content is a major holding update, not a general announcement.
2018-12-13 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It details the acquisition/disposal of shares by Invesco Ltd., crossing a threshold (3.001949900583%) on November 29, 2018. This directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification category (MRQ). Although the header mentions 'Voting Rights Announcements', the content structure is a standard major holding disclosure.
2018-12-06 English
MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018 (news with additional features)
Regulatory Filings Classification · 99% confidence The document is a news release dated December 2, 2018, announcing updated clinical data (L-MIND study results for MOR208) presented at the American Society of Hematology (ASH) 2018 Annual Meeting. It contains key efficacy and safety results (ORR, mPFS, DoR, TEAEs) and discusses future development plans. This format—a press release detailing specific scientific/clinical results outside of a formal quarterly or annual filing—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on clinical trial data presentation rather than comprehensive financial performance for a reporting period (like 10-K or IR), and it is an initial announcement of results, 'ER' (Earnings Release) is the closest fit among the options, although 'RNS' (Regulatory Filings) is also plausible for non-standard announcements. Given the structure mimicking an earnings-style release highlighting key data points, ER is selected, as these often accompany or precede formal financial reports when clinical milestones are hit.
2018-12-02 English
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a 'News Details' release dated November 26, 2018, announcing the regulatory approval of Tremfya (Guselkumab) in Japan. It contains keywords like 'DGAP-News', 'Regulatory Approval', and discusses a specific medical/product development event. This format, which is a formal announcement of a significant corporate event (regulatory milestone) distributed via a news service (DGAP/EQS Group), strongly suggests a general regulatory announcement or news release that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement of a regulatory event but not a specific financial filing, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory news releases not covered by other specific codes.
2018-11-26 English
MorphoSys to Present at Upcoming Investor Conferences
Regulatory Filings Classification · 100% confidence The document is a news release titled "MorphoSys to Present at Upcoming Investor Conferences." It details the specific dates, venues, and participating executives for several upcoming investor and analyst events (e.g., ASH Annual Meeting, Berenberg European Conference, JPMorgan Annual Healthcare Conference). This type of announcement, which informs the market about management's schedule for engaging with investors, is best classified as an Investor Presentation (IP) announcement or, more broadly, a general corporate announcement. Since the document itself is not the presentation material but an announcement *about* presentations, and it doesn't fit the strict definitions of ER, IR, or 10-K, it is a corporate communication regarding investor engagement. Given the options, 'Investor Presentation' (IP) is the most relevant category, as the core subject is management's plan to present to investors. However, since the document is an announcement of *future* presentations rather than the presentation itself, and it is disseminated via DGAP (a regulatory news service), it could also be considered a Regulatory Filing (RNS). Given the specific content focuses entirely on investor engagement schedules, IP is a strong fit, but RNS is the general catch-all for such news releases. Since the content is highly specific to investor meetings, I will lean towards IP, as it signals future investor interaction, which is a key component of investor relations materials.
2018-11-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.